These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8958953)

  • 21. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI; Bourne N
    J Immunol; 1998 Jun; 160(12):6093-100. PubMed ID: 9637526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.
    Parr EL; Parr MB
    Immunology; 1999 Dec; 98(4):639-45. PubMed ID: 10594699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production in macrophages.
    Paludan SR; Ellermann-Eriksen S; Mogensen SC
    J Gen Virol; 1998 Nov; 79 ( Pt 11)():2785-93. PubMed ID: 9820155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of resistant mucocutaneous herpes simplex infections in AIDS patients: a clinical and virological challenge.
    Barde C; Piguet V; Pechère M; Masouye I; Saurat JH; Wunderli W; Kaiser L; Toutous Trellu L
    HIV Med; 2011 Jul; 12(6):367-73. PubMed ID: 21251181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2.
    Nishimura H; Yajima T; Kagimoto Y; Ohata M; Watase T; Kishihara K; Goshima F; Nishiyama Y; Yoshikai Y
    J Virol; 2004 May; 78(9):4927-30. PubMed ID: 15078977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical alpha-interferon ointment with dimethyl sulfoxide in the treatment of recurrent genital herpes simplex.
    Shupack J; Stiller M; Davis I; Kenny C; Jondreau L
    Dermatology; 1992; 184(1):40-4. PubMed ID: 1558994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
    Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
    Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus.
    Tsunobuchi H; Nishimura H; Goshima F; Daikoku T; Suzuki H; Nakashima I; Nishiyama Y; Yoshikai Y
    Virology; 2000 Sep; 275(1):57-66. PubMed ID: 11017787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could zinc oxide tetrapod nanoparticles be used as an effective immunotherapy against HSV-2?
    Yadavalli T; Shukla D
    Nanomedicine (Lond); 2016 Sep; 11(17):2239-42. PubMed ID: 27527812
    [No Abstract]   [Full Text] [Related]  

  • 31. Early resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferon.
    Bird MD; Chu CF; Johnson AJ; Milligan GN
    J Virol; 2007 Jan; 81(1):423-6. PubMed ID: 17065206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice.
    Parr MB; Parr EL
    Virology; 1999 Jun; 258(2):282-94. PubMed ID: 10366565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research in simple blind with natural interferon alpha at low dosage on subjects affected by labialis and genitalis herpes simplex.
    Scalvenzi M; Ceddia C
    Clin Ter; 2000; 151(1 Suppl 1):13-8. PubMed ID: 10876961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
    Cortesi R; Ravani L; Rinaldi F; Marconi P; Drechsler M; Manservigi M; Argnani R; Menegatti E; Esposito E; Manservigi R
    Int J Pharm; 2013 Jan; 440(2):229-37. PubMed ID: 22743007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation.
    Thebeau LG; Morrison LA
    J Virol; 2003 Feb; 77(4):2426-35. PubMed ID: 12551980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.
    Carr DJ; Tomanek L; Silverman RH; Campbell IL; Williams BR
    J Virol; 2005 Jul; 79(14):9341-5. PubMed ID: 15994831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
    Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
    Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI
    Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.